A detailed history of Vident Advisory, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 144,089 shares of GILD stock, worth $17.9 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
144,089
Previous 68,295 110.98%
Holding current value
$17.9 Million
Previous $7.57 Billion 111.23%
% of portfolio
0.15%
Previous 0.09%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$108.22 - $120.47 $8.2 Million - $9.13 Million
75,794 Added 110.98%
144,089 $16 Billion
Q2 2025

Aug 14, 2025

BUY
$96.91 - $113.0 $2.79 Million - $3.25 Million
28,788 Added 72.87%
68,295 $7.57 Billion
Q1 2025

May 15, 2025

BUY
$89.14 - $117.41 $1.22 Million - $1.61 Million
13,679 Added 52.96%
39,507 $4.43 Billion
Q4 2024

Feb 14, 2025

SELL
$83.95 - $97.9 $2.44 Million - $2.85 Million
-29,112 Reduced 52.99%
25,828 $2.39 Billion
Q3 2024

Nov 14, 2024

BUY
$66.59 - $83.99 $1.65 Million - $2.08 Million
24,824 Added 82.43%
54,940 $4.61 Billion
Q2 2024

Aug 14, 2024

SELL
$63.15 - $72.88 $615,586 - $710,434
-9,748 Reduced 24.45%
30,116 $2.07 Billion
Q1 2024

May 14, 2024

SELL
$71.58 - $87.29 $4.96 Million - $6.04 Million
-69,227 Reduced 63.46%
39,864 $2.92 Billion
Q4 2023

Feb 14, 2024

BUY
$73.27 - $83.09 $92,759 - $105,191
1,266 Added 1.17%
109,091 $8.84 Billion
Q3 2023

Feb 21, 2024

SELL
$73.94 - $80.67 $93,608 - $102,128
-1,266 Reduced 1.16%
107,825 $8.08 Billion
Q3 2023

Nov 14, 2023

BUY
$73.94 - $80.67 $7.97 Million - $8.7 Million
107,825 New
107,825 $8.08 Billion

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $156B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Vident Advisory, LLC Portfolio

Follow Vident Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Advisory, LLC with notifications on news.